Loading clinical trials...
Loading clinical trials...
A Prospective, Multicenter Phase II Clinical Study of Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB Driver Gene-negative Non-small Cell Lung Cancer (NSCLC)
Conditions
Interventions
Atezolizumab
Locations
1
China
Hunan Cancer hospital
Changsha, Hunan, China
Start Date
February 1, 2023
Primary Completion Date
December 1, 2024
Completion Date
July 1, 2025
Last Updated
September 19, 2024
NCT07485114
NCT06066138
NCT05098132
NCT06284317
NCT06731413
NCT06687369
Lead Sponsor
Hunan Province Tumor Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions